OASM Oasmia Pharmaceutical AB

Oasmia postpones the release of the Q4 and year-end report to 28 June

Oasmia postpones the release of the Q4 and year-end report to 28 June

The Board of Oasmia has decided to postpone the release of the fourth quarter and year-end 2018/2019 report from 5 June 2019 to 28 June 2019. The delay is a result of the ongoing review initiated by the new Board in March 2019. There are a number of time-consuming and outstanding investigations and evaluations that need to be finalized, decided upon and accordingly rightly valued in the accounts. Those involved in this process include the management, the board, specialists consulted as well as the auditors.

“Due to outstanding issues in the review, and also to make sure that fact-based decisions can be made, the Board has decided to postpone the release of the year-end report,” says Jörgen Olsson, Chairman of Oasmia.

The ongoing review includes both valuation issues in the balance sheet as well as strategic planning discussions. The latter are conducted in co-operation with former Chairman of the Board and the CFO.

The outcome of the review and initiatives initiated by Oasmia’s new Board will communicated to the market as soon as there is relevant information to be shared. 

For further information, please contact

About Oasmia Pharmaceutical AB 

Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

Information is also available at -frankfurt.de twitter.com/oasmia

This information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST on 15 May 2019.

Attachment

EN
15/05/2019

Underlying

OASMOasmia Pharmaceutical AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oasmia Pharmaceutical AB

Sean Conroy
  • Sean Conroy
OASM Oasmia Pharmace...

Vivesto - Termination of coverage

Edison Investment Research is terminating coverage on Vivesto (VIVE), Diurnal Group (DNL), Palace Capital (PCA), Primary Health Properties (PHP), Silver One Resources (SVE), Induction Healthcare (INHC) and Axiom European Financial Debt (AXI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

OASM OASMIA PHARMACEUTICAL AB
02/01/23 February 1, 2023 1 EN
Sean Conroy
  • Sean Conroy
OASM Oasmia Pharmace...

Vivesto - Turnaround strategy beginning to deliver

Vivesto capped off its 18-month strategic turnaround with reduced Q1 losses and a stated focus on its ‘string of pearls’ strategy to build its oncology pipeline through in-licensing and M&A. In March, it successfully completed a rights issue, generating net proceeds of SEK134.6m, extending its runway into 2024. This is sufficient to cover a number of clinical and commercial inflection points and execute its strategy. Key upcoming catalysts include the planned 2022 UK and German launches of Apeal...

OASM OASMIA PHARMACEUTICAL AB
06/27/22 June 27, 2022 1 EN
Sean Conroy
  • Sean Conroy
OASM Oasmia Pharmace...

Oasmia Pharmaceutical - Delivering on promises

FY21 results highlight delivery on key elements of Oasmia’s ongoing transformation. Notably, ‘rightsizing’ the business and prudent cost control has brought the underlying cash burn rate down to c SEK10m per month in 2021. With the fully secured rights issue expected to raise gross proceeds of c SEK150m, management has guided it can fund operations for 18–24 months. We anticipate material progression can be made across the pipeline during this time, with clinical progress expected from Cantrixil...

OASM OASMIA PHARMACEUTICAL AB
02/25/22 February 25, 2022 1 EN
Sean Conroy
  • Sean Conroy
OASM Oasmia Pharmace...

Oasmia Pharmaceutical - Rights issues secured and planned for Q122

Oasmia has announced it has secured a preferential, one-for-five rights issue that will raise gross proceeds of c SEK151m and should alleviate near-term funding requirements. The company’s largest shareholder has agreed to subscribe to its allotment (24.8%) and a consortium of external investors has guaranteed the remainder (75.2%), albeit on a 6.5% cash compensation basis. Subscription rights can be traded from 8 to 17 March. Oasmia has also announced plans to change its name to Vivesto; both t...

OASM OASMIA PHARMACEUTICAL AB
01/20/22 January 20, 2022 1 EN
Sean Conroy
  • Sean Conroy
OASM Oasmia Pharmace...

Oasmia Pharmaceutical - Rights issues secured and planned for Q122

Oasmia has announced it has secured a preferential, one-for-five rights issue that will raise gross proceeds of c SEK151m and should alleviate near-term funding requirements. The company’s largest shareholder has agreed to subscribe to its allotment (24.8%) and a consortium of external investors has guaranteed the remainder (75.2%), albeit on a 6.5% cash compensation basis. Subscription rights can be traded from 8 to 17 March. Oasmia has also announced plans to change its name to Vivesto; both t...

OASM OASMIA PHARMACEUTICAL AB
01/20/22 January 20, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch